TIDMVRP 
 
   LONDON, April 23, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) 
(Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on respiratory diseases,  announces that it will report 
its audited financial results for the three months ended March 31, 2020 
on Thursday, April 30, 2020 and host an investment community conference 
call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss the financial results 
and provide a corporate update. 
 
   To participate, please dial one of the following numbers and reference 
conference ID 2667888: 
 
 
   -- 866-940-4574 for callers in the United States 
 
   -- 0800 028 8438 for callers in the United Kingdom 
 
   -- 0800 181 5287 for callers in Germany 
 
 
   A live webcast will be available on the Events and Presentations link on 
the Investors page of the Company's website, 
https://www.globenewswire.com/Tracker?data=ssqFVlkm7mXk1L1Ba-690fKqST3L0EtJAjEyh61Yfrg4sFZB5kFguneEA0MRTprVtvfumkVtHzZFJ9ZvQEuM7vHN-g6TomXAvTcbkXVzOUM= 
www.veronapharma.com, and an audio replay will be available there for 30 
days. 
 
   About Verona Pharma 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. If 
successfully developed and approved, Verona Pharma's product candidate, 
ensifentrine, has the potential to be the first therapy for the 
treatment of respiratory diseases that combines bronchodilator and 
anti-inflammatory activities in one compound. Verona Pharma is currently 
evaluating three formulations of ensifentrine for the treatment of COPD 
in Phase 2 clinical trials: nebulized, dry powder inhaler, and 
pressurized metered-dose inhaler. Ensifentrine also has potential 
applications in cystic fibrosis, asthma and other respiratory diseases. 
For more information, please visit www.veronapharma.com. 
 
 
 
 
 
  Verona Pharma plc                                         Tel: +44 (0)20 3283 4200 
------------------------------------------------------    --------------------------- 
  Victoria Stewart, Director of Communications              info@veronapharma.com 
------------------------------------------------------    --------------------------- 
 
  N+1 Singer                                                Tel: +44 (0)20 3283 4200 
   (Nominated Adviser and UK Broker) 
------------------------------------------------------    --------------------------- 
  Aubrey Powell / George Tzimas / Iqra Amin (Corporate 
   Finance) 
------------------------------------------------------    --------------------------- 
  Tom Salvesen (Corporate Broking) 
------------------------------------------------------    --------------------------- 
 
  Optimum Strategic Communications                          Tel: +44 (0)20 950 9144 
   (European Media and Investor Enquiries)                   verona@optimumcomms.com 
------------------------------------------------------    --------------------------- 
  Mary Clark / Eva Haas / Hollie Vile 
------------------------------------------------------    --------------------------- 
 
  Argot Partners                                            Tel: +1 212-600-1902 
   (US Investor Enquiries)                                   verona@argotpartners.com 
------------------------------------------------------    --------------------------- 
  Kimberly Minarovich / Michael Barron 
------------------------------------------------------    ---------------------------

(END) Dow Jones Newswires

April 23, 2020 02:00 ET (06:00 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Verona Pharma Charts.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Verona Pharma Charts.